Business Wire

Gilead Sciences Announces Changes to Senior Leadership Team

Share

Gilead Sciences, Inc. (Nasdaq: GILD) announced today changes to the company’s senior leadership team. Gregg Alton, Chief Patient Officer, and Katie Watson, Executive Vice President, Human Resources, will be departing Gilead. Jyoti Mehra has been named Executive Vice President, Human Resources, and will assume responsibility for the worldwide HR function.

Mr. Alton joined Gilead in 1999 and most recently has led Gilead’s corporate and medical affairs functions and developing world access programs, as well as commercial operations in certain countries of Asia and Latin America. He previously served as general counsel and helped to architect the company’s innovative access model for HIV and viral hepatitis medicines in resource-limited countries. He will remain with Gilead through October 4 and plans to serve in an advisory capacity until the end of the year to help transition his responsibilities to other parts of the organization.

“Gregg has been a valued leader at Gilead for nearly 20 years,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead. “His unwavering focus on enabling and expanding access to medicines has allowed the company to help millions of individuals in countries most heavily impacted by HIV, hepatitis B and hepatitis C. I want to thank Gregg for his many contributions and tireless advocacy.”

“I am honored to have had the opportunity to help lead Gilead for nearly two decades,” said Mr. Alton. “On behalf of the organizations I have had a chance to lead, I am extraordinarily proud of the work we have done together to drive innovative solutions to reach the people most in need of our medications around the world.”

Ms. Watson joined Gilead in 2003 and during her 16 years with the company has helped to support significant organizational growth around the world. She has been responsible for attracting, developing and retaining talent, and delivering a strategic approach to engaging the company’s employees. She has helped to foster a culture that builds on Gilead’s core values of inclusion, teamwork, excellence, accountability and integrity.

“Katie has had a tremendous impact on Gilead, and I would like to thank her for her many contributions, including her dedication to improving the experience for the more than 11,000 employees at our company,” commented Mr. O’Day. “It is a testament to her leadership and her skill in developing people that we were quickly able to identify a strong successor. I know Jyoti will build on the important work underway to ensure Gilead is considered among the best places to work in our industry.”

“Helping Gilead grow and hire so many talented individuals and working to develop and retain our employees has been a privilege for the past 16 years,” commented Ms. Watson. “I am deeply appreciative of the opportunity to be a part of a company that has transformed care for patients, and I am confident our HR organization will continue contributing to this mission.”

Effective August 5, Ms. Mehra will be appointed as Ms. Watson’s successor. Ms. Watson will depart Gilead on September 1, remaining with Gilead in an advisory capacity through the end of the year to ensure a smooth transition. Ms. Mehra joined Gilead in 2017 as Vice President, Human Resources. She has more than 20 years of experience building organizational capabilities and shaping high-performing teams and cultures. She has worked across the United States, Europe and Asia. Prior to joining Gilead, she held positions of increasing seniority at Novartis Pharmaceuticals Corp. and Eli Lilly & Co.

“It is a great privilege to take on this role and to lead Gilead’s Human Resources organization,” said Ms. Mehra. “As a company, Gilead has enjoyed tremendous success because of the smart and talented people who work here. It is truly an honor to have the opportunity to continue to shape Gilead’s culture in this position and to build on the company’s strong past by adding organizational capabilities.”

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1 800-GILEAD-5 or 1-650-574-3000.

Contact information

Sung Lee, Investors
(650) 524-7792

Amy Flood, Media
(650) 522-5643

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CES Unveiled in Paris to Shine Spotlight on Artificial Intelligence26.8.2019 10:00:00 EESTPress release

Consumer Technology Association (CTA)®: WHAT: The Consumer Technology Association (CTA)® today announced that CES Unveiled in Paris will focus on emerging technology and trends around artificial intelligence (AI). More than 1,000 expected attendees will be able to view the latest AI innovations, learn about the latest tech trends and network with industry leaders. An official CES 2020 preview, CES Unveiled returns to Paris for a seventh year on Tuesday, Oct. 22 at Palais Brongniart. Attendees will experience a full day of tech that will feature more than 80 companies of all sizes, influential media, senior level executives, and prominent industry influencers from France and across Europe. Attendees will discover how AI is shaping our world, from changing enterprises to affecting ethics and policy. Industry experts and thought leaders from all over Europe will share insights on AI, enterprise solutions, mobility, Internet of Things (IoT) infrastructure, autonomous vehicles, diversity an

Study Investigates the Utility of Masimo ORi™, Oxygen Reserve Index, to Reduce Hyperoxia in Critically Ill Patients26.8.2019 09:00:00 EESTPress release

Masimo (NASDAQ: MASI) announced today that in a randomized controlled study involving 150 ICU patients recently published as a letter in Intensive Care Medicine, researchers investigated whether monitoring with Masimo ORi™ (Oxygen Reserve Index) could reduce the time critically ill patients spend with moderate hyperoxia, compared to monitoring with oxygen saturation (SpO2) alone.1 ORi is an index of oxygenation in the moderate hyperoxic region, defined as arterial partial pressure of oxygen, PaO2 , in the range of 100 to 200 mmHg). As an “index” with a scale between 0.0 and 1.0, ORi can be trended to notify clinicians of changes in a patient’s oxygen reserve. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190825005030/en/ Masimo Root® and Radical-7® with ORi™ (Photo: Business Wire) Dr. Sigismond Lasocki and colleagues at the Centre Hospitalier Universitaire of Angers, France (CHU Angers), sought to evaluate whether controlli

S BLOCK 1000 Pax Interstellar Quantitative Summit Convenes in Bangkok26.8.2019 08:24:00 EESTPress release

On August 21st, "S BLOCK Interstellar Quantitative Summit" officially convened in Bangkok, Thailand! This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190825005035/en/ (PHOTO: S BLOCK) Interstellar Quantification Assists S BLOCK to be Further Technologized S BLOCK is a brand-new multi-currency, cross-chain technology wallet from Switzerland, which jointly issued by S BLOCK foundation, Cloud Capital, Top Line, DAF, Stanford Blockchain Research center, MIT Media Lab and Cambridge Financial Alternative Center. Since its launch on June 15, it has bring an generous revenue of 6-15% per month for its millions of users. Interstellar quantification is S BLOCK's biggest source of revenue. Interstellar quantification is to realize timely capital exchanges with the quantification team under the agreement of Interstellar loan contract, so as to enlarge the capital scale at the fastest speed and lock up trading opportunities addition, S Blo

Building The Data Economy Within The G726.8.2019 08:00:00 EESTPress release

Under the French Presidency, the G7 summit in Biarritz brings together the heads of state and government of the largest economies. This summit comes three months after the digital technology ministers meeting of G7 countries in Paris where the need to strengthen international digital cooperation was a key focal point of the debates. Discussions are still ongoing to resolve the challenges of the data economy, and the free flow of data in a trusted environment. Several international initiatives in favor of data circulation took place in recent months. As part of the Digital Single Market, the European Commission announced a new regulation on the free flow of non-personal data. The United States initiated a federal plan for data strategy. At the G20, Japan proposed the Osaka Track initiative to standardize the international rules for data flow. According to Dawex, the leading data exchange technology company and operator of the largest data marketplace, the flow of data in the G7 countrie

Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration23.8.2019 23:01:00 EESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on July 14, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190823005335/en/ This agreement has received clearance from the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and merger control approval from the Austrian Federal Competition Authority. Under the terms of the agreement, the closing of this transaction triggers an upfront license fee payment of $3.95 billion by Gilead to Galapagos. In addition, Gilead has made an equity investment in Galapagos of approximately $1.1 billion (or approximately €960 million) by subscribing for new shares at a price of €140.59 per share, including issuance premium. As a result, Gilead now owns 13,589,686 ordinary shares of Galapagos, representing approximately 2

32 Leading Global Fashion and Textile Companies Make Commitments on Climate, Biodiversity and Oceans23.8.2019 10:47:00 EESTPress release

Ahead of the G7 meeting at Biarritz from August 24-26, French President Emmanuel Macron, accompanied by Economy and Finance Minister Bruno Le Maire, Minister of Labour Muriel Pénicaud, and Deputy Minister of Ecological and Solidary Transition Brune Poirson, has invited to the Elysée Palace representatives of the 32 fashion and textile companies who have launched the Fashion Pact by his side. In April 2019, ahead of the G7 meeting, Emmanuel Macron had given François-Henri Pinault, Chairman and Chief Executive Officer of Kering (Paris:KER), a mission to bring together the leading players in fashion and textile, with the aim of setting practical objectives for reducing the environmental impact of their industry. In a historic move, given the scale and importance of the coalition that has been created, 32 leading companies from the fashion and textile industry have given themselves a set of shared objectives in the form of a Fashion Pact. The coalition includes groups and brands in Luxury,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom